{"database":"Cell Collective","file_versions":[],"scores":null,"additional":{"omics_type":["Models"],"submitter":["Audrey Crowther"],"version_name":[""],"full_dataset_link":["https://cellcollective.org/#2202/neurotransmitter-signaling-pathway"],"model_score":["9.122800000000002"],"default_version":["1"],"ModelFormat":["SBML"],"submitter_affiliation":[""],"submitter_email":[""],"version_id":["1"],"repository":["Cell Collective"],"version_url":["https://cellcollective.org/#2202:1/neurotransmitter-signaling-pathway"],"version_description":[""],"pubmed_abstract":["<h4>Background</h4>A Boolean network is a simple computational model that may provide insight into the overall behavior of genetic networks and is represented by variables with two possible states (on/off), of the individual nodes/genes of the network. In this study, a Boolean network model has been used to simulate a molecular pathway between two neurotransmitter receptor, dopamine and glutamate receptor, systems in order to understand the consequence of using logic gate rules between nodes, which have two possible states (active and inactive).<h4>Results</h4>The dynamical properties of this Boolean network model of the biochemical pathway shows that, the pathway is stable and that, deletion/knockout of certain biologically important nodes cause significant perturbation to this network. The analysis clearly shows that in addition to the expected components dopamine and dopamine receptor 2 (DRD2), Ca(2+) ions play a critical role in maintaining stability of the pathway.<h4>Conclusion</h4>So this method may be useful for the identification of potential genetic targets, whose loss of function in biochemical pathways may be responsible for disease onset. The molecular pathway considered in this study has been implicated with a complex disorder like schizophrenia, which has a complex multifactorial etiology."],"pubmed_title":["Boolean network analysis of a neurotransmitter signaling pathway."],"pubmed_authors":["Gupta Simone S, Bisht Siddharth S SS, Kukreti Ritushree R, Jain Sanjeev S, Brahmachari Samir K SK"],"description_synonyms":["Deoxyepinephrine, Aluminum, Materials, glutamic acid dianion, Disorders, ion, determination, Glu, Receptors, Neuromediator, glutamate, Techniques, unspecified, 2-diol, 2-Aminoglutaric acid, Dementia Praecox, Hydroxytyramine, diseases, Roles, Method, Aluminum L-Glutamate, Dopamine Receptors, chronic state, 1, Concepts, pathogenesis, unspecified state, 3, diseases and disorders, 4-(2-aminoethyl)-1, Unspecified schizophrenia, 4-(2-Aminoethyl)-1, Neuroregulators Receptors, Synaptic, SCHIZOPHRENIA NEC-UNSPEC, Neuromodulator Receptors, E, human disease, Unspecified schizophrenia (disorder), CALCIUM ION, Schizophrenic disorders, 2-Benzenediol, Age of onset, genetic, Neuroregulator Receptor, Neuromodulator Receptor, Dopamine, Drd-2, Methodological Studies, Role Concepts, Neurotransmitters, Homo sapiens disease, Glutaminic acid, SIMPLE, dopamina, dopamine, single-organism behavior, SCHIZO NOS-SUBCHR/EXACER, 4-(2-aminoethyl)-, hydrogen glutamate, Process, familial, 2-(3, L-Glutamic Acid, Synaptic Receptor, Procedure, results, Acceptance Processes, doubly charged positive ion, Neurohumor, Acceptance Process, Role Concept, Ionen, Playthings and Play, PIG7, Potassium Glutamate, SCHIZOPHRENIA NEC-SUBCHR, Dopamine Receptor, Diseases, Role, Plaything, Schizophrenias, Genetic Materials, Neuromodulator, 4-(2-aminoethyl)pyrocatechol, D Glutamate, Genetic Material, Synaptic Receptors, [X]Schizophrenia, Neuromediators, 4 Dihydroxyphenethylamine, susceptibility to, Toys, Methodological, Ca(2+), Neurotransmitters Receptors, Methodological Study, (D)-Isomer, L-Glutamic acid, loss of, Schizophrenic Disorders, calcium, disease, Material, Neuromediator Receptors, Neuroregulators, 2-ammoniopentanedioate, D-Glutamate, Cistron, 4-Dihydroxyphenyl)ethylamine, chronic state with acute exacerbation, inherited genetic, DL-Glutamic acid, glutamic acid, other disease, 4-Dihydroxyphenethylamine, Plays, Logics, Procedures, Neurohumor Receptors, 2-aminopentanedioate, Processes, Gene, Aluminum L Glutamate, unspecified (disorder), schizophrenia with or without an affective disorder, method, Schizophrenia NOS, Ca2+, SCHIZO NOS-CHR/EXACERB, method used in an experiment, Other specified types of schizophrenia, Studies, disease or disorder, causality., subchronic state, Technique, 4-(2-aminoethyl)catechol, Toy, Glutamic acid, study, Schizophrenia (disorder), Genetic, Playthings, Hydroxytyramin, iones, Schizophrenic Disorder, causes, Neuromodulators Receptors, Intropin, ions, SCZD, glutamate(2-), schizoaffective disorder, non-neoplastic, Study, D2DR, Puppets, Disorder, Neuroregulator Receptors, Play, d2dr, disorder, drd2, Behaviors, Neurotransmitter, SCHIZOPHRENIA NEC-REMISS, constitutitional genetic, Potassium, Puppet, TP53I7, Neuromediators Receptors, SCHIZO NEC-CHR/EXACERB, Dopamine Hydrochloride, schizophrenia, SCHIZO NEC-SUBCHR/EXACER, disorders, glutamate(1-), 4-(2-Aminoethyl)benzene-1, function, medical condition, Cistrons, Neurotransmitter Receptor, Concept, Neuromodulators, D2R, Glutamate, Schizophrenic disorders (disorder), chemical analysis, SCHIZOPHRENIA NEC-CHR, Hydrochloride, Glutamic Acid, condition, background, subchronic state with acute exacerbation, Glutaminsaeure, L-Glutamate, L Glutamic Acid, Acceptance, DL-Glutaminic acid, 2-aminopentanedioic acid, 4-dihydroxyphenyl)ethylamine, Schizophrenic, 3-Hydroxytyramine, Neurotransmitter Receptors, Schizophrenia NOS (disorder), Age symptoms begin, introduction, plan specification, in remission, dopaminum, 2-benzenediol, glutamic acid monoanion, d2r, Ion, DEL, L Glutamate, Receptor, assay, Neuromediator Receptor, SCHIZOPHRENIA NOS-UNSPEC, hereditary, Neuroregulator"],"pubmed_title_synonyms":["signal transduction by protein phosphorylation, network topology analysis, Neurotransmitter Agent, Neurohumors, Nerve, Substances, signal transduction by conformational transition, neurotransmitters, Substance, signal transduction by trans-phosphorylation., Neurohumor, signaling cascade, signalling pathway, Neuromodulators, Nerve Transmitter, signaling pathway, Nerve Transmitter Substance, Transmitter Substances, Neuroregulators, Transmitter Substance, Neurotransmitters, signal transduction by cis-phosphorylation, Neuromodulator, Nerve Transmitter Substances, Neurohormones, Neurotransmitter, signalling cascade, Neurohormone, Neuroregulator"],"name_synonyms":["signal transduction by protein phosphorylation, Neurotransmitter Agent, Neurohumors, Nerve, Substances, signal transduction by conformational transition, neurotransmitters, Substance, signal transduction by trans-phosphorylation., Neurohumor, signaling cascade, signalling pathway, Neuromodulators, Nerve Transmitter, signaling pathway, Nerve Transmitter Substance, Transmitter Substances, Neuroregulators, Transmitter Substance, Neurotransmitters, signal transduction by cis-phosphorylation, Neuromodulator, Nerve Transmitter Substances, Neurohormones, Neurotransmitter, signalling cascade, Neurohormone, Neuroregulator"],"pubmed_abstract_synonyms":["biochemical pathways, Deoxyepinephrine, Aluminum, Materials, glutamic acid dianion, Disorders, ion, determination, Glu, Receptors, Neuromediator, glutamate, Techniques, unspecified, 2-diol, 2-Aminoglutaric acid, Dementia Praecox, Hydroxytyramine, diseases, Roles, Method, Aluminum L-Glutamate, Dopamine Receptors, chronic state, 1, Concepts, pathogenesis, unspecified state, 3, diseases and disorders, 4-(2-aminoethyl)-1, Unspecified schizophrenia, 4-(2-Aminoethyl)-1, Neuroregulators Receptors, Synaptic, SCHIZOPHRENIA NEC-UNSPEC, Neuromodulator Receptors, E, human disease, Unspecified schizophrenia (disorder), CALCIUM ION, catabolism, Schizophrenic disorders, 2-Benzenediol, Age of onset, genetic, Neuroregulator Receptor, Neuromodulator Receptor, Dopamine, Drd-2, Methodological Studies, Role Concepts, Neurotransmitters, biotransformation, Homo sapiens disease, Glutaminic acid, SIMPLE, dopamina, dopamine, single-organism behavior, SCHIZO NOS-SUBCHR/EXACER, 4-(2-aminoethyl)-, hydrogen glutamate, Process, familial, 2-(3, L-Glutamic Acid, Synaptic Receptor, Procedure, results, Acceptance Processes, doubly charged positive ion, Neurohumor, Acceptance Process, Role Concept, Ionen, PIG7, Potassium Glutamate, SCHIZOPHRENIA NEC-SUBCHR, Dopamine Receptor, Diseases, Role, Schizophrenias, Genetic Materials, secretion, Neuromodulator, 4-(2-aminoethyl)pyrocatechol, D Glutamate, Genetic Material, Synaptic Receptors, [X]Schizophrenia, Neuromediators, 4 Dihydroxyphenethylamine, susceptibility to, Methodological, Ca(2+), Neurotransmitters Receptors, Methodological Study, (D)-Isomer, L-Glutamic acid, loss of, Schizophrenic Disorders, calcium, disease, Material, Neuromediator Receptors, Neuroregulators, 2-ammoniopentanedioate, D-Glutamate, Cistron, 4-Dihydroxyphenyl)ethylamine, chronic state with acute exacerbation, inherited genetic, DL-Glutamic acid, glutamic acid, other disease, 4-Dihydroxyphenethylamine, Logics, Procedures, Neurohumor Receptors, 2-aminopentanedioate, Processes, Gene, Aluminum L Glutamate, unspecified (disorder), schizophrenia with or without an affective disorder, method, Schizophrenia NOS, Ca2+, SCHIZO NOS-CHR/EXACERB, method used in an experiment, Other specified types of schizophrenia, Studies, disease or disorder, causality., subchronic state, Technique, 4-(2-aminoethyl)catechol, Glutamic acid, study, Schizophrenia (disorder), Genetic, Hydroxytyramin, iones, Schizophrenic Disorder, causes, Neuromodulators Receptors, Intropin, ions, SCZD, glutamate(2-), schizoaffective disorder, non-neoplastic, Study, D2DR, Disorder, Neuroregulator Receptors, d2dr, disorder, drd2, Behaviors, Neurotransmitter, SCHIZOPHRENIA NEC-REMISS, constitutitional genetic, Potassium, TP53I7, Neuromediators Receptors, SCHIZO NEC-CHR/EXACERB, Dopamine Hydrochloride, degradation, schizophrenia, SCHIZO NEC-SUBCHR/EXACER, disorders, glutamate(1-), 4-(2-Aminoethyl)benzene-1, function, medical condition, Cistrons, Neurotransmitter Receptor, Concept, Neuromodulators, D2R, Glutamate, Schizophrenic disorders (disorder), chemical analysis, SCHIZOPHRENIA NEC-CHR, Hydrochloride, Glutamic Acid, condition, background, subchronic state with acute exacerbation, Glutaminsaeure, L-Glutamate, L Glutamic Acid, Acceptance, DL-Glutaminic acid, 2-aminopentanedioic acid, 4-dihydroxyphenyl)ethylamine, biodegradation, Schizophrenic, 3-Hydroxytyramine, Neurotransmitter Receptors, Schizophrenia NOS (disorder), Age symptoms begin, introduction, plan specification, in remission, dopaminum, 2-benzenediol, glutamic acid monoanion, d2r, Ion, DEL, L Glutamate, Receptor, assay, Neuromediator Receptor, SCHIZOPHRENIA NOS-UNSPEC, hereditary, Neuroregulator"],"additional_accession":[]},"is_claimable":false,"name":"Neurotransmitter Signaling Pathway","description":"Background  A Boolean network is a simple computational model that may provide insight into the overall behavior of genetic networks and is represented by variables with two possible states (on/off), of the individual nodes/genes of the network. In this study, a Boolean network model has been used to simulate a molecular pathway between two neurotransmitter receptor, dopamine and glutamate receptor, systems in order to understand the consequence of using logic gate rules between nodes, which have two possible states (active and inactive).  Results  The dynamical properties of this Boolean network model of the biochemical pathway shows that, the pathway is stable and that, deletion/knockout of certain biologically important nodes cause significant perturbation to this network. The analysis clearly shows that in addition to the expected components dopamine and dopamine receptor 2 (DRD2), Ca2+ ions play a critical role in maintaining stability of the pathway. Conclusion  So this method may be useful for the identification of potential genetic targets, whose loss of function in biochemical pathways may be responsible for disease onset. The molecular pathway considered in this study has been implicated with a complex disorder like schizophrenia, which has a complex multifactorial etiology.","dates":{"created":"2013-08-02","publication":"","submission":"2018-08-05","last_modified":"2018-08-05"},"accession":"2202","cross_references":{"pubmed":["17010384"]}}